Top Tweets for #Mibc
Clinical Decision-Making with ctDNA in #BladderCancer Practice.
Can ctDNA guide escalation or de-escalation in #MIBC? Seth Lerner, MD, FACS, @apolo_andrea, and Jeffrey Ross, MD, Dec (HC), join @shilpaonc to discuss clinical decision-making with ctDNA in bladder cancer practice. #IBCG26 #WatchNow > https://t.co/O8KBXBsOwA @UroDocAsh

#CUAJHighLightedPaper Association between time from diagnosis to radical #cystectomy and oncologic outcomes in muscle-invasive urothelial carcinoma of the bladder , to real full article: https://t.co/6YTUEO8q1S
#MIBC

Perioperative EV-Based Treatment Options for Cisplatin-Ineligible #MIBC - Amanda Nizam (@AmandaNizamMD)
https://t.co/3x3cGoev8D

⭐🟠 #UromigosLive 2026 | Nashville 🇺🇸🎸
🚨 ADAPT-MIBC: WHAT IF PERSISTENT ctDNA SHOULD CHANGE OUR TREATMENT STRATEGY?
🎙️ @OncoAlert | An innovative phase II trial concept presented by Suzanne Cole, mentored by @PGrivasMDPhD!
🔬 A NEW APPROACH TO #MIBC
🧬 Persistent ctDNA positivity after neoadjuvant systemic therapy identifies a challenging clinical scenario.
📊 THE PROPOSED ADAPT-MIBC DESIGN
✅ MIBC with detectable ctDNA at baseline/during neoadjuvant treatment.
✅ Following 3–4 cycles of systemic therapy, patients with persistently positive ctDNA enter an adaptive treatment strategy.
✅ Switch systemic therapy until:
• ctDNA becomes undetectable
• Unacceptable toxicity
• Disease progression
✅ Definitive local therapy: radical cystectomy or chemoradiotherapy.
📈 THE HYPOTHESIS
🎯 Target 2-year EFS: 66%
📉 Null benchmark: 55%
🔬 Planned HR assumption: 0.70
Real-world cohorts provide observational context.
⚠️ These are proposed design assumptions—not efficacy results.
💡 MY CLINICAL PEARL
Should persistent molecular residual disease trigger a change in treatment BEFORE definitive local therapy?
🔥 Moving from ctDNA as a prognostic biomarker to a potential therapeutic decision tool!
👏 An exciting question that deserves prospective investigation.
@tompowles1 @brian_rini @Uromigos
@MattGalsky @MichvdHeijden @DrRosenbergMSK @JoshMeeks @shilpaonc @urotoday @ecancer @UrologyTimes
#BladderCancer #GUOnc #PrecisionOncology #ctDNA #ClinicalTrials #OncoAlert
@LosUromigos

⭐🟠 #UromigosLive | #MIBC
🚀 KEYNOTE-992 • EV-209 • TROFUSE-055 • EV-309
@LosUromigos @Uromigos
🔬 Can we spare the bladder without compromising cure?
💡 A complete clinical response is not proof that cystectomy can safely be omitted.
@OncoAlert @tompowles1 @PGrivasMDPhD @kalasri3

⭐🧬 #UromigosLive | #MIBC
🔬 KEYNOTE-B15:
✅ ctDNA clearance: 82.1% EV+pembro vs 66.7% chemo
✅ pCR if pre-op ctDNA−: 72.4% vs 43.7%
⚠️ If ctDNA+: just 3.7% vs 2.2%
💡 Molecular response ≠ a validated de-escalation strategy.
@OncoAlert @JoshMeeks @LosUromigos @Uromigos

⭐🟠 #UromigosLive | Perioperative #MIBC
🔥 Two powerful signals:
✅ VOLGA: EFS HR 0.51 | OS HR 0.58
✅ KN905/EV303: EFS HR 0.40 | OS HR 0.50
⚠️ Not head-to-head.
💡 The next question is patient selection.
@OncoAlert @tompowles1 @DrRosenbergMSK @LosUromigos @Uromigos

⭐🟠 #UromigosLive | #MIBC
📊 NIAGARA: EFS HR 0.68 | OS HR 0.75
⚠️ ENERGIZE & KEYNOTE-866 tell different stories.
💡 pCR improvement alone ≠ survival benefit. Cross-trial comparisons demand caution.
@OncoAlert @tompowles1 @MattGalsky @Uromigos @LosUromigos

⭐🟠 #UromigosLive 2026 | Nashville 🇺🇸
🔥 BLADDER PRESERVATION: ARE WE READY FOR THE NEXT PARADIGM SHIFT?
🎙️ @tompowles1 keeps the discussion sharp, dynamic & thought-provoking with @JoshMeeks @kalasri3 @PGrivasMDPhD and Anna Wilkins!
🔬 FOUR TRIALS TO WATCH IN #MIBC:
✅ KEYNOTE-992: TMT ± pembrolizumab.
✅ EV-209: Phase II, N=240. EV + pembro, assessing cCR and 2-year bladder-intact EFS.
✅ TROFUSE-055: Sacituzumab tirumotecan + pembrolizumab with CRT.
✅ EV-309: Phase III, EV + pembro vs concurrent CRT.
🔎 THE BIG QUESTIONS:
🔹 Can we safely omit cystectomy in selected patients?
🔹 How reliably can we define cCR?
🔹 Will ctDNA and utDNA improve patient selection?
🔹 What level of long-term evidence is needed?
💡 MY CLINICAL PEARL:
Preserving the bladder is not enough. We must preserve the chance of cure.
🎯 Organ preservation, oncologic safety and quality of life must move forward together.
⚠️ Promising trials—not yet definitive evidence for omitting cystectomy.
🔥 Outstanding science, different viewpoints, clever questions and a lively exchange that challenges conventional thinking!
🚀 This is why #UromigosLive is so special!
@Uromigos @tompowles1 @brian_rini @OncoAlert @MattGalsky @MichvdHeijden @shilpaonc @DrRosenbergMSK @JoshMeeks @kalasri3 @PGrivasMDPhD @yao_zhu_sh @AttardLab @dr_coops @NehaVapiwala @TDorffOnc @neerajaiims @lalaniMD @DrKarieRuncie @TiansterZhang @MVossMD @montypal @HHammersMD @AlbigesL @ViktorGruenwald
#UroVoices #BladderCancer #GUOnc
⭐🟠 #UromigosLive 2026 | Nashville 🇺🇸
🚨 ¿ESTAMOS ANTE UNA NUEVA ERA EN LA PRESERVACIÓN VESICAL?
🔥 ¡Un intercambio científico extraordinario sobre uno de los grandes desafíos del #MIBC!
🎙️ @tompowles1 conduce un debate lleno de preguntas incisivas, perspectivas diferentes y argumentos brillantes con @JoshMeeks @kalasri3 @PGrivasMDPhD y Anna Wilkins.
🔬 CUATRO ENSAYOS QUE PODRÍAN CAMBIAR EL PARADIGMA:
✅ KEYNOTE-992: TMT ± pembrolizumab.
✅ EV-209: EV + pembrolizumab. Fase II, N=240. Evaluación de respuesta clínica completa y supervivencia con vejiga intacta.
✅ TROFUSE-055: sacituzumab tirumotecán + pembrolizumab y quimiorradioterapia.
✅ EV-309: EV + pembrolizumab vs quimiorradioterapia. Fase III.
🔎 LAS GRANDES PREGUNTAS:
🔹 ¿Podremos evitar la cistectomía en pacientes seleccionados?
🔹 ¿Cómo definiremos una cCR confiable?
🔹 ¿Qué aportarán ctDNA y utDNA?
🔹 ¿Cómo garantizamos el control oncológico a largo plazo?
💡 MENSAJE CLÍNICO:
¡Preservar la vejiga es mucho más que obtener una respuesta completa!
🎯 El verdadero objetivo es preservar el órgano sin comprometer la supervivencia ni la calidad de vida.
⚠️ Estas nuevas estrategias continúan en investigación.
🚀 ¡Ciencia rigurosa, diferentes puntos de vista y preguntas que impulsan la innovación!
🌎 ¡El futuro de la oncología GU se construye con colaboración internacional!
@Uromigos @OncoAlert @MattGalsky @MichvdHeijden @shilpaonc @DrRosenbergMSK @yao_zhu_sh @brian_rini @AttardLab @dr_coops @NehaVapiwala @TDorffOnc @neerajaiims @lalaniMD @DrKarieRuncie @TiansterZhang @MVossMD @montypal @HHammersMD @AlbigesL @ViktorGruenwald
@ecancer_espanol @sogug1 @_SEOM @SMEOMX @SolcaGuayaquil @LACOG_group @SChOncologia
#CancerDeVejiga #OncologiaGU

⭐🟠 #UromigosLive 2026 | Nashville 🇺🇸
🚨 ¿ESTAMOS ANTE UNA NUEVA ERA EN LA PRESERVACIÓN VESICAL?
🔥 ¡Un intercambio científico extraordinario sobre uno de los grandes desafíos del #MIBC!
🎙️ @tompowles1 conduce un debate lleno de preguntas incisivas, perspectivas diferentes y argumentos brillantes con @JoshMeeks @kalasri3 @PGrivasMDPhD y Anna Wilkins.
🔬 CUATRO ENSAYOS QUE PODRÍAN CAMBIAR EL PARADIGMA:
✅ KEYNOTE-992: TMT ± pembrolizumab.
✅ EV-209: EV + pembrolizumab. Fase II, N=240. Evaluación de respuesta clínica completa y supervivencia con vejiga intacta.
✅ TROFUSE-055: sacituzumab tirumotecán + pembrolizumab y quimiorradioterapia.
✅ EV-309: EV + pembrolizumab vs quimiorradioterapia. Fase III.
🔎 LAS GRANDES PREGUNTAS:
🔹 ¿Podremos evitar la cistectomía en pacientes seleccionados?
🔹 ¿Cómo definiremos una cCR confiable?
🔹 ¿Qué aportarán ctDNA y utDNA?
🔹 ¿Cómo garantizamos el control oncológico a largo plazo?
💡 MENSAJE CLÍNICO:
¡Preservar la vejiga es mucho más que obtener una respuesta completa!
🎯 El verdadero objetivo es preservar el órgano sin comprometer la supervivencia ni la calidad de vida.
⚠️ Estas nuevas estrategias continúan en investigación.
🚀 ¡Ciencia rigurosa, diferentes puntos de vista y preguntas que impulsan la innovación!
🌎 ¡El futuro de la oncología GU se construye con colaboración internacional!
@Uromigos @OncoAlert @MattGalsky @MichvdHeijden @shilpaonc @DrRosenbergMSK @yao_zhu_sh @brian_rini @AttardLab @dr_coops @NehaVapiwala @TDorffOnc @neerajaiims @lalaniMD @DrKarieRuncie @TiansterZhang @MVossMD @montypal @HHammersMD @AlbigesL @ViktorGruenwald
@ecancer_espanol @sogug1 @_SEOM @SMEOMX @SolcaGuayaquil @LACOG_group @SChOncologia
#CancerDeVejiga #OncologiaGU

🚨 The @FDA has approved neoadjuvant #durvalumab plus enfortumab vedotin followed by adjuvant durvalumab for adults with #MIBC who are ineligible for or decline cisplatin-based chemotherapy, expanding perioperative treatment options. Learn more: https://t.co/oBoBUqDEzp

⭐🟠 #UromigosLive 2026 | Nashville 🇺🇸
🔥 SHARP QUESTIONS, DIFFERENT PERSPECTIVES & A TRULY RICH SCIENTIFIC EXCHANGE!
🎙️ @OncoAlert @tompowles1 brilliantly moderates a lively #MIBC debate with @MattGalsky @DrRosenbergMSK & @MichvdHeijden.
🔬 EV + PEMBROLIZUMAB vs EV + DURVALUMAB: WHAT HAVE WE LEARNED?
📊 KEYNOTE-905/EV-303:
✅ EFS HR 0.40 | OS HR 0.50
📊 VOLGA (EV + durvalumab):
✅ EFS HR 0.51 | OS HR 0.58
⚠️ Cross-trial comparisons: HANDLE WITH CARE!
🔎 THE REAL QUESTIONS:
🔹 Does failure to achieve pCR justify continued adjuvant therapy?
🔹 Can ctDNA guide treatment decisions?
🔹 How do efficacy, toxicity & treatment completion influence our choices?
💡 MY CLINICAL PEARL:
The challenge is not simply achieving pCR, but understanding residual disease, selecting the right patients and translating responses into durable survival benefit.
🔥 Different viewpoints, thoughtful challenges, clever answers—and @tompowles1 keeping everyone on their toes!
🚀 This is what makes Uromigos so special!
@brian_rini
@Uromigos @shilpaonc @montypal @TiansterZhang @neerajaiims @katy_beckermann @PGrivasMDPhD @TwoOncDocs @DrKarineTawagi @Dr_Aggen @AmandaNizamMD
@lalaniMD @NazliDizman @weoncologists @LosUromigos @urotoday @UrologyTimes
#UroVoices #BladderCancer #GUOnc
⭐🟠 #UromigosLive 2026 | Nashville 🇺🇸
🔥 ¡PREGUNTAS SAGACES, DISTINTAS PERSPECTIVAS Y UN INTERCAMBIO CIENTÍFICO EXTRAORDINARIO!
🎙️ @tompowles1 modera con su estilo inconfundible un debate apasionante junto a @MattGalsky @DrRosenbergMSK y @MichvdHeijden.
🔬 ¿CÓMO ESTÁ CAMBIANDO EL PARADIGMA DEL MIBC?
📊 KEYNOTE-905/EV-303:
✅ EFS HR 0,40 | OS HR 0,50
📊 VOLGA (EV + durvalumab):
✅ EFS HR 0,51 | OS HR 0,58
⚠️ ¡Cuidado con las comparaciones indirectas entre ensayos!
🔎 LAS GRANDES CONTROVERSIAS:
🔹 ¿Qué hacer cuando no se alcanza pCR?
🔹 ¿Podrá el ctDNA orientar la adyuvancia?
🔹 ¿Cómo equilibrar eficacia, toxicidad y duración del tratamiento?
💡 MENSAJE CLÍNICO:
No basta con alcanzar una respuesta patológica. El desafío es identificar qué pacientes necesitan tratamiento adicional y cómo convertir las respuestas en beneficios duraderos.
🚀 ¡Perspectivas diferentes, argumentos sólidos y respuestas brillantes!
🌎 ¡Así se construye la ciencia: debatiendo, cuestionando y compartiendo conocimiento!
@Uromigos @OncoAlert @PGrivasMDPhD @ecancer_espanol @sogug1 @_SEOM @SMEOMX @SolcaGuayaquil @crisuarez08
#CancerDeVejiga #OncologiaGU

🚨 The @FDA approved perioperative durvalumab + enfortumab vedotin for cisplatin-ineligible patients with #MIBC.
The phase 3 VOLGA trial demonstrated improved event-free and overall survival. #FDA #BladderCancer #Oncology
Read more: https://t.co/ndgc9WPDfz
⭐🟠 #UromigosLive 2026 | Nashville 🇺🇸
🔥 SHARP QUESTIONS, CLEVER ANSWERS & PRACTICE-CHANGING DEBATES!
🎙️ @OncoAlert | @tompowles1 at his best! Incisive questions, challenging assumptions & keeping everyone on their toes!
🔬 Brilliant #MIBC discussion with @MattGalsky @MichvdHeijden & @shilpaonc.
📊 PERIOPERATIVE IMMUNOTHERAPY: NOT ALL TRIALS TELL THE SAME STORY!
✅ NIAGARA: EFS HR 0.68 | OS HR 0.75
🔹 KEYNOTE-866: EFS HR 0.88 | OS HR 1.00
🔹 ENERGIZE: EFS HR 0.94 | OS HR 0.88
⚠️ Similar pCR improvements, but different survival outcomes! Cross-trial comparisons require caution.
💡 **MY CLINICAL PEARL:**
Improving pCR does not necessarily translate into better survival. Timing, treatment strategy & patient selection matter!
🚀 Outstanding science, thoughtful controversy & a discussion that never loses momentum!
@Uromigos @LosUromigos @PGrivasMDPhD @JoshMeeks @kalasri3 @urotoday @UrologyTimes
#UroVoices #BladderCancer #GUOnc
⭐🟠 #UromigosLive 2026 | Nashville 🇺🇸
🔥 ¡NO TODAS LAS ESTRATEGIAS PERIOPERATORIAS SON IGUALES EN MIBC!
🎙️ ¡Debate de altísimo nivel!
@tompowles1 modera con preguntas incisivas, respuestas inteligentes y un ritmo que no da tregua.
🔬 @MattGalsky @MichvdHeijden y @shilpaonc analizan 15 ensayos fase III de inmunoterapia en cáncer urotelial.
📊 EL GRAN CONTRASTE:
✅ NIAGARA: HR EFS 0,68 | OS 0,75
🔹 KEYNOTE-866: HR EFS 0,88 | OS 1,00
🔹 ENERGIZE: HR EFS 0,94 | OS 0,88
⚠️ ¡Mejorar la pCR no garantiza un beneficio en supervivencia!
💡 LA GRAN PREGUNTA:
¿Qué determina el éxito de la inmunoterapia perioperatoria: el fármaco, el momento del tratamiento o la biología tumoral?
🚀 ¡Ciencia, controversia y pensamiento crítico en estado puro!
@Uromigos @OncoAlert @PGrivasMDPhD @ecancer_espanol @sogug1 @_SEOM @SMEOMX @SolcaGuayaquil
#CancerDeVejiga #OncologiaGU

🚨 #FDAApproval: The @FDA has granted approval for durvalumab + enfortumab vedotin before surgery, followed by durvalumab after cystectomy, for cisplatin-ineligible/refusing adults with #MIBC.
Approval supported by phase III VOLGA trial findings.
https://t.co/rYWQdkCcU6

SunRISe-4 Examines Neoadjuvant Cetrelimab and Gem-iDRS Prior to Cystectomy in Cisplatin-Ineligible Patients.
SunRISe-4 perioperative outcomes in cisplatin-ineligible #MIBC. @spsutkaMD @uwurology joins @UroCancerMD @VUMChealth to discuss neoadjuvant TAR-200 + cetrelimab: 85.2% reached cystectomy within the protocol window, similar to cetrelimab alone. #WatchNow > https://t.co/MUEBOJHPVV

🧬 Could response-adapted therapy help more patients with #BladderCancer avoid cystectomy?
@AndreaNecchi MD, discusses treatment de-escalation and future strategies to improve complete response rates in #MIBC.
🎥 WATCH: https://t.co/5PmVitLNbt #ESMO26 #Oncology

NIAGARA Trial Explores Urinary Tumor DNA as a Biomarker in Bladder Cancer.
Urinary tumor DNA in #MIBC from NIAGARA. @MichvdHeijden @NKI_nl joins @ERPlimackMD @FoxChaseCancer to discuss utDNA and ctDNA with perioperative durvalumab. pCR was 72% if utDNA-negative vs 18% if positive. #WatchNow on UroToday > https://t.co/fbbqDNpUGh

Defining clinical complete response after neoadjuvant therapy in #MIBC. @TomFlaigMD @CUAnschutz and @CMercinelli @SanRaffaeleMI join @pjhensley11 @UKYMedicine at #IBCG2026; Dr. Flaig calls #IMvigor011 a turning point for ctDNA. #WatchNow on UroToday > https://t.co/LMHl8IeTpF #IBCG26 @IBCG_BladderCA

Last Seen Hashtags on Sotwe
brosis
Seen from Netherlands
ميقا_حصريات
Seen from France
bully #BBC
Seen from Austria
nolimit()************************************* filter:native_video
Seen from United Kingdom
Whore
Seen from France
spy #caught
Seen from Israel
isappuas2
Seen from Malaysia
tru kait
Seen from Oman
PowerBalladMovie
Seen from United States
Most Popular Users

Elon Musk 
@elonmusk
240.5M followers

Barack Obama 
@barackobama
118.7M followers

Cristiano Ronaldo 
@cristiano
114.4M followers

Donald J. Trump 
@realdonaldtrump
111.8M followers

Narendra Modi 
@narendramodi
107M followers

Rihanna 
@rihanna
98.7M followers

NASA 
@nasa
92.2M followers

Justin Bieber 
@justinbieber
91.8M followers

KATY PERRY 
@katyperry
90M followers

Taylor Swift 
@taylorswift13
84M followers

Lady Gaga 
@ladygaga
75.5M followers

Virat Kohli 
@imvkohli
73.4M followers

Kim Kardashian 
@kimkardashian
70.8M followers

YouTube 
@youtube
68.7M followers

Neymar Jr 
@neymarjr
66.4M followers

Bill Gates 
@billgates
65.2M followers

Selena Gomez 
@selenagomez
63M followers

The Ellen Show
@theellenshow
62.1M followers

CNN 
@cnn
61.7M followers

X 
@x
60.6M followers















